5995-28-8

Usage

Uses

Used in Medical Applications:
BMBP is used as a therapeutic agent for conditions such as osteoporosis and Paget's disease. It functions by strengthening bones and slowing down the breakdown of bone tissue. The application reason is its mechanism of action, which involves binding to the bone mineral and inhibiting the activity of osteoclasts, the cells responsible for bone resorption.
Used in Dental Care:
In the dental industry, BMBP is used as a preventive agent for bone loss associated with periodontal disease. The application reason is its ability to inhibit bone resorption, which can help maintain the health of the jawbone and prevent the deterioration of dental structures.
Overall, [(butylimino)bis(methylene)]bisphosphonic acid (BMBP) is a significant compound with potential applications in various therapeutic and pharmaceutical contexts, particularly in the fields of medicine and dental care.

InChI:InChI=1/C6H17NO6P2/c1-2-3-4-7(5-14(8,9)10)6-15(11,12)13/h2-6H2,1H3,(H2,8,9,10)(H2,11,12,13)

Upstream product

• 50-00-0 formaldehyd 
• 109-73-9 N-butylamine 

Relevant academic research and scientific papers

Two new layered lead(II) diphosphonates with 1,3,5-benzenetricarboxylate ligands as an intercalated species or a multidentate metal linker

Hydrothermal reactions of lead(II) carbonate with 1,3,5- benzenetricarboxylic acid (H3BTC) and butylimino- bis(methylenephosphonic acid) (CH3CH2CH2CH 2N(CH2PO3H2)2, H 4L1) or lead(II) acetate with H3BTC and isobutylimino-bis(methylenephosphonic acid) (Me2CHCH 2N(CH2PO3H2)2, H 4L2) afforded two novel lead(II) carboxylate phosphonate hybrids, namely, Pb5(HL1)2(L 1)·H3BTC 1 and Pb4(BTC)(L 2)(CH3CO2)(H2O)2· 1.5H2O 2. The structure of compound 1 contains a 〈002〉 lead(II) diphosphonate hybrid layer formed by Pb(II) ions interconnected by HL1 and L1 anions. In compound 2, the interconnection of Pb(II) ions through bridging diphosphonate L2 anions lead to the formation of the 〈200〉 lead(II) diphosphonate 2D layer. In compound 1, the 1,3,5-benzenetricarboxylic acid acts as an intercalated species whereas in compound 2, the 1,3,5-benzenetricarboxylate anion adopts a hexadentate chelating and bridging coordination mode.

Study on the synergistic antibacterial effect of silver-carried layered zirconium alkyl-N,N-dimethylenephosphonate

A series of zirconium alkyl-N,N-dimethylenephosphonate silver-carrying (Ag-ZRDP) were successfully prepared and their potential applications as synergistic antibacterial materials were investigated. Silver nanoparticles (Ag NPs), of 30 nm in diameter, were tightly anchored onto the zirconium alkyl-N,N-dimethylenephosphonate (ZRDP), increasing the antibacterial activity of the Ag NPs due to a decrease in the extent of nanoparticle aggregation. Due to the synergistic antibacterial effect of the Ag NPs and ZRDP, the Ag-ZRDP showed a better antibacterial activity than Ag NPs and ZRDP with a minimal inhibition concentration (MIC) of 0.25 and 0.25 μg mL-1 against Escherichia coli and Staphylococcus aureus, respectively. Additionally, the Ag-ZRDP did not show obvious cytotoxicity against mammalian cells (A549 cells), even at a concentration of 256 μg mL-1. Collectively, these properties make the newly synthesized Ag-ZRDP potentially superior as disinfectants and antiseptics for various biomedical and biotechnological applications.